Why Novartis Stock Could Fall Next: Bearish Drivers Ahead

01. Historical Context

Why the current setup could evolve into a deeper drawdown

The bearish setup for Novartis is easier to define because the stock starts from a richer valuation and a stronger 10-year run. At CHF 118.04 on May 15, 2026, investors were still paying a quality multiple despite a negative Q1 print.

That negative print matters. Q1 2026 net sales were USD 13.1 billion, down 5% at constant currencies, while core EPS was USD 1.99, down 15% at constant currencies. The drag came from US generic erosion, but priority brands still grew strongly: Kisqali +55% cc, Pluvicto +70%, Kesimpta +26%, Scemblix +79%, and Leqvio +69%. In other words, the portfolio is healthy, but the reported P&L is still exposed to a live erosion cycle.

That is the essence of the bear case: if the market decides the normalization timeline is too optimistic, a quality stock can still de-rate materially.

Bearish setup for Novartis using current verified datapoints — Downside framework anchored to the current price, recent operating data, and today's valuation setup.

Novartis framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were USD 13.1 billion, down 5% at constant currencies, while core EPS was USD 1.99, down 15% at constant currencies.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Novartis at about 19.2x trailing 2025 earnings, 20.1x 2026 estimated earnings, and 17.3x 2027 estimated earnings. Consensus EPS on MarketScreener was USD 7.244 for 2026 and USD 8.433 for 2027, implying roughly 16.4% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2030	Structural compounding	10-year price range CHF 39.77 to CHF 126.65; 10-year CAGR 10.0%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five bearish forces that could pull the stock lower

The first bearish force is obvious: US generic erosion. It was large enough in Q1 2026 to overwhelm impressive growth elsewhere.

The second bearish force is valuation. Around 20x 2026 EPS is fine when investors trust the bridge, but it can compress quickly if trust slips.

The third bearish force is margin pressure. Core operating income was down 14% at constant currencies in Q1 2026, so there is no room for the market to dismiss profitability pressure as purely cosmetic.

The fourth bearish force is sector breadth. FactSet still flags healthcare as one of the weakest sectors on earnings breadth, which makes negative surprises more dangerous.

The fifth bearish force is execution risk around the longer-term growth plan. If the 5%-6% sales CAGR bridge starts to look too ambitious, the stock will lose one of its main supports.

Current factor scorecard for Novartis

Factor	Current Assessment	Bias	Why it matters now
US generic erosion	Q1 sales -5% cc	Bearish	The problem is current, measurable, and already in the numbers.
Valuation	About 20.1x 2026 EPS	Bearish	The stock is not cheap enough to absorb repeated weak quarters easily.
Margin pressure	Q1 core operating income -14% cc; margin 37.3%	Bearish	The market needs to see recovery.
Long-term guide	5%-6% sales CAGR through 2030	Bullish offset	This limits the bear case if investors keep trusting it.
Sector tape	Healthcare still weak in FactSet data	Bearish	The backdrop is not forgiving.

03. Countercase

What could invalidate the bearish thesis

The bearish setup weakens quickly if management proves Q1 2026 was the trough. This is not a business under structural collapse; it is a business working through an erosion pocket.

A second reason to avoid overplaying the bear case is brand quality. Kisqali, Pluvicto, Kesimpta, Scemblix, and Leqvio are still putting up the kind of growth rates that many large pharma peers would want.

The most credible bearish stance is therefore conditional, not absolute: bearish if erosion and margin pressure persist, neutral if they normalize on schedule.

Current constraints on the bear case

Risk	Latest datapoint	Current assessment	Bias
Trough-quarter risk	Q1 2026 may prove the low point	Bearish case weakens if true	Neutral
Brand quality	Five priority brands still growing double digits	Offsets part of the downside	Bullish offset
Guide credibility	Management reaffirmed FY 2026 guidance	Still intact	Neutral
Multiple cushion	Less cushion than Sanofi	Real downside sensitivity	Bearish

04. Institutional Lens

What named research says about the downside case

The institutional bear lens is stronger for Novartis than for Sanofi because consensus is only Hold and the market already gives Novartis credit for quality.

FactSet's healthcare breadth data and the IMF's downside macro framing both matter here because they make it harder for the stock to maintain a premium multiple during weak reported growth.

At the same time, J.P. Morgan's relative valuation work and Novartis' own medium-term CAGR guide argue against a structural-collapse view. That is why the bear case should stay tied to measured triggers, not headlines.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	On May 7, 2026, MarketScreener listed 22 analysts on the Novartis ADR with a Hold consensus, average target USD 155.06, low target USD 121.07, and high target USD 178.42.	Analysts see only modest upside on the ADR, which implies the market already gives meaningful credit to quality and capital returns.	That makes execution on priority brands and generic erosion the main swing factors.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

How to define the downside case with measurable triggers

The right bearish process is to watch whether Q1 2026 was a one-quarter reset or the start of a longer revision cycle. That means tracking the next two quarterly prints and whether the market continues to trim 2027 EPS estimates.

Because the stock is closer to its decade highs, a failed normalization story can produce a sharper downside air pocket than in Sanofi.

Bearish scenario map for Novartis

Scenario	Probability	Target range	Trigger	When to review
Bearish follow-through	35%	CHF 95 to CHF 108	Generic erosion persists and the market takes the multiple below 18x.	Review after Q2 2026 and any guidance change.
Sideways pressure	40%	CHF 108 to CHF 120	Quality and dividends keep the floor intact, but reported growth remains too soft for a rerating.	Review after FY 2026.
Bear case fails	25%	Above CHF 120	The business normalizes faster than expected and investors look through the weak quarter.	Review if brand growth remains strong and guidance holds.